Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Lankenau Institute for Medical Research holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently in the prosecution pipeline. These actions are assigned to a matching number of distinct examiners and are located within 2 distinct art units.
ORWIG, KEVIN S is the busiest examiner, currently managing 1 busiest examiner pending office action. As the total workload is split, the other action is handled by a different examiner. This distribution across multiple art units means that the Biotechnology & Pharmaceuticals portfolio is being evaluated by different technical teams at the patent office.
For those managing this portfolio, the 2 pending office actions necessitate coordination across different examination environments. The use of multiple distinct examiners highlights the variety in the institute's current research output. Practitioners must be prepared for different examiner perspectives given that each active matter is in a separate art unit.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORWIG, KEVIN S | 1 | 25.5% | +40.1% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18491078 | Nucleic Acid Molecules Encoding Indoleamine 2,3-Dioxygenase-2 | ORWIG, KEVIN S | 49d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18491078 | Nucleic Acid Molecules Encoding Indoleamine 2,3-Dioxygenase-2 | ORWIG, KEVIN S | 49d overdue |
| 18004618 | COMPOSITIONS COMPRISING ANTIBODIES TO HUMAN IDO-2 | STONEBRAKER, ALYSSA RAE | 8d overdue |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18491078 | Nucleic Acid Molecules Encoding Indoleamine 2,3-Dioxygenase-2 | ORWIG, KEVIN S | 3991 | §101§102 | Non-Final OA | 49d overdue | Pending | Oct 20, 2023 |
| 18004618 | COMPOSITIONS COMPRISING ANTIBODIES TO HUMAN IDO-2 | STONEBRAKER, ALYSSA RAE | 1642 | §112 | Final Rejection | 8d overdue | Pending | Jan 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial